Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 3/20 | 0.33 |
| ▸ | CTSS | P25774 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1687973 | 1.00 | KMT2A (0.39) | KMT2AMEN1MAPK1LPAR1BTK | |
| SCHEMBL1636182 | 1.00 | KMT2A (0.39) | KMT2AMEN1MAPK1LPAR1BTK | |
| SCHEMBL12891851 | 1.00 | KMT2A (0.39) | KMT2AMEN1MAPK1LPAR1BTK | |
| SCHEMBL28564855 | 0.89 | KMT2A (0.40) | KMT2AMEN1MAPK1BTKALDH1A1 | |
| SCHEMBL7897717 | 0.88 | KMT2A (0.38) | KMT2AMEN1MAPK1BTKALDH1A1 | |
| SCHEMBL14631900 | 0.88 | LPAR1 (0.34) | LPAR1 | |
| SCHEMBL12891846 | 0.88 | KMT2A (0.39) | KMT2AMEN1MAPK1ALDH1A1CACNA1H | |
| SCHEMBL6838872 | 0.88 | MEN1 (0.39) | KMT2AMEN1MAPK1BTKGAA | |
| SCHEMBL6838875 | 0.88 | MEN1 (0.39) | KMT2AMEN1MAPK1BTKGAA | |
| SCHEMBL6237174 | 0.88 | MEN1 (0.39) | KMT2AMEN1MAPK1BTKGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2028186-B1 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM CA LTD (CA) | 2013-01-23 | — | — | EP | claimed |
| EP-2028186-B1 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM CA LTD (CA) | 2013-01-23 | — | — | EP | disclosed |
| EP-2028186-B1 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM CA LTD (CA) | 2013-01-23 | — | — | EP | disclosed |
| EP-2379579-A1 | HCV NS3 PROTEASE INHIBITORS | Gilead Sciences, Inc. (US) | 2011-10-26 | — | — | EP | disclosed |
| US-RE42164-E1 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2011-02-22 | — | — | US | disclosed |
| US-RE42164-E1 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2011-02-22 | — | — | US | disclosed |
| US-RE41894-E1 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2010-10-26 | — | — | US | disclosed |
| US-RE41894-E1 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2010-10-26 | — | — | US | disclosed |
| US-RE41894-E1 | Hepatitis C inhibitor tri-peptides | BOEHRINGER INGELHEIM CANADA LTD. (CA) | 2010-10-26 | — | — | US | disclosed |
| WO-2010080389-A1 | HCV NS3 PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20020037998-A1 | Hepatitis C inhibitor tri-peptides | LLINAS-BRUNET MONTSE (CA) | 2002-03-28 | — | — | US | disclosed |
| US-20020016442-A1 | Hepatitis C inhibitor tri-peptides | LLINAS-BRUNET MONTSE (CA) | 2002-02-07 | — | — | US | disclosed |
| US-6329379-B1 | OLIGOPEPTIDES FOR INHIBITING HEPATITIS | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-12-11 | — | — | US | disclosed |
| US-6329417-B1 | RACEMATES, DIASTEREOISOMERS AND OPTICAL ISOMERS; PROTEASE INHIBITOR PEPTIDE ANALOG | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-12-11 | — | — | US | disclosed |
| US-6323180-B1 | PROTEASE INHIBITORS; INHIBIT REPLICATION OF HEPATITIS C VIRUS | BOEHRINGER INGELHEIM (CANADA) LTD (CA) | 2001-11-27 | — | — | US | disclosed |
| US-6268207-B1 | RESOLUTION OF ENANTIOMERS FROM A MIXTURE OF (1R,2S)/(1S,2S)-1-AMINO-2-VINYLCYCLOPROPYL CARBOXYLIC ACID METHYL ESTER COMPRISING THE STEP OF TREATING SAID MIXTURE WITH AN ESTERASE TO OBTAIN THE CORRESPONDING (1R,2S) ENANTIOMER | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-07-31 | — | — | US | disclosed |
| EP-1105422-A1 | HEPATITIS C INHIBITOR PEPTIDES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-06-13 | — | — | EP | disclosed |
| EP-1105413-A2 | HEPATITIS C INHIBITOR TRI-PEPTIDES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2001-06-13 | — | — | EP | disclosed |
| WO-2000009558-A1 | HEPATITIS C INHIBITOR PEPTIDES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-02-24 | — | — | WO | disclosed |
| WO-2000009543-A2 | HEPATITIS C INHIBITOR TRI-PEPTIDES | BOEHRINGER INGELHEIM (CANADA) LTD. (CA) | 2000-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037998-A1 | Hepatitis C inhibitor tri-peptides | LIPC, HAVCR2, HCCS | KMT2A 4757/4885MEN1 4494/4885MAPK1 1745/4885 |
| US-20020016442-A1 | Hepatitis C inhibitor tri-peptides | HAVCR2, LIPC, HCCS | KMT2A 4759/4885MEN1 4480/4885MAPK1 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.